Literature DB >> 27321643

Automated Microchromatography Enables Multiplexing of Immunoaffinity Enrichment of Peptides to Greater than 150 for Targeted MS-Based Assays.

Paul J Ippoliti1, Eric Kuhn1, D R Mani1, Lola Fagbami1, Hasmik Keshishian1, Michael W Burgess1, Jacob D Jaffe1, Steven A Carr1.   

Abstract

Immunoaffinity enrichment of peptides coupled with analysis by stable isotope dilution multiple reaction mass spectrometry has been shown to have analytical performance and detection limits suitable for many biomarker verification studies and biological applications. Prior studies have shown that antipeptide antibodies can be multiplexed up to 50 in a single assay without significant loss of performance. Achieving higher multiplex levels is relevant to all studies involving precious biological material as this minimizes the amount of sample that must be consumed to measure a given set of analytes and reduces the assay cost per analyte. Here we developed automated methods employing the Agilent AssayMAP Bravo microchromatography platform and used these methods to characterize the performance of immunoaffinity enrichment of peptides up to multiplex levels of 172. Median capture efficiency for the target peptides remained high (88%) even at levels of 150-plex and declined to 70% at 172-plex compared to antibody performance observed at standard lower multiplex levels (n = 25). Subsequently, we developed and analytically characterized a multiplexed immuno-multiple reaction monitoring-mass spectrometry (immuno-MRM-MS) assay (n = 110) and applied it to measure candidate protein biomarkers of cardiovascular disease in plasma of patients undergoing planned myocardial infarction. The median lower limit of detection of all peptides was 71.5 amol/μL (nM), and the coefficient of variation (CV) was less than 15% at the lower limit of quantification. The results demonstrate that high multiplexed immuno-MRM-MS assays are readily achievable using the optimized sample processing and peptide capture methods described here.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27321643     DOI: 10.1021/acs.analchem.6b00946

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  14 in total

1.  Development of a Multiplexed Assay for Oral Cancer Candidate Biomarkers Using Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry.

Authors:  Yung-Chin Hsiao; Lang-Ming Chi; Kun-Yi Chien; Wei-Fan Chiang; Szu-Fan Chen; Yao-Ning Chuang; Shih-Yu Lin; Chia-Chun Wu; Ya-Ting Chang; Lichieh Julie Chu; Yi-Ting Chen; Shu-Li Chia; Chih-Yen Chien; Kai-Ping Chang; Yu-Sun Chang; Jau-Song Yu
Journal:  Mol Cell Proteomics       Date:  2017-08-18       Impact factor: 5.911

2.  Mass Spectrometry-Based Plasma Proteomics: Considerations from Sample Collection to Achieving Translational Data.

Authors:  Vera Ignjatovic; Philipp E Geyer; Krishnan K Palaniappan; Jessica E Chaaban; Gilbert S Omenn; Mark S Baker; Eric W Deutsch; Jochen M Schwenk
Journal:  J Proteome Res       Date:  2019-10-11       Impact factor: 4.466

Review 3.  Strategies for mass spectrometry-based phosphoproteomics using isobaric tagging.

Authors:  Xinyue Liu; Rose Fields; Devin K Schweppe; Joao A Paulo
Journal:  Expert Rev Proteomics       Date:  2021-10-28       Impact factor: 3.940

Review 4.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

5.  A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage.

Authors:  Jeffrey R Whiteaker; Lei Zhao; Rick Saul; Jan A Kaczmarczyk; Regine M Schoenherr; Heather D Moore; Corey Jones-Weinert; Richard G Ivey; Chenwei Lin; Tara Hiltke; Kerryn W Reding; Gordon Whiteley; Pei Wang; Amanda G Paulovich
Journal:  Radiat Res       Date:  2018-02-23       Impact factor: 2.841

Review 6.  Advances in quantitative high-throughput phosphoproteomics with sample multiplexing.

Authors:  Joao A Paulo; Devin K Schweppe
Journal:  Proteomics       Date:  2021-03-30       Impact factor: 3.984

7.  Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.

Authors:  Adam S Sperling; Michael Burgess; Hasmik Keshishian; Jessica A Gasser; Shruti Bhatt; Max Jan; Mikołaj Słabicki; Rob S Sellar; Emma C Fink; Peter G Miller; Brian J Liddicoat; Quinlan L Sievers; Rohan Sharma; Dylan N Adams; Elyse A Olesinski; Mariateresa Fulciniti; Namrata D Udeshi; Eric Kuhn; Anthony Letai; Nikhil C Munshi; Steven A Carr; Benjamin L Ebert
Journal:  Blood       Date:  2019-05-01       Impact factor: 25.476

8.  Proteomic analysis of human lacrimal and tear fluid in dry eye disease.

Authors:  Jae Hun Jung; Yong Woo Ji; Ho Sik Hwang; Jae Won Oh; Hyun Chang Kim; Hyung Keun Lee; Kwang Pyo Kim
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

9.  Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles.

Authors:  Claudia Fredolini; Sanna Byström; Laura Sanchez-Rivera; Marina Ioannou; Davide Tamburro; Fredrik Pontén; Rui M Branca; Peter Nilsson; Janne Lehtiö; Jochen M Schwenk
Journal:  Sci Rep       Date:  2019-06-06       Impact factor: 4.379

10.  Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona.

Authors:  John E Blume; William C Manning; Gregory Troiano; Daniel Hornburg; Michael Figa; Lyndal Hesterberg; Theodore L Platt; Xiaoyan Zhao; Rea A Cuaresma; Patrick A Everley; Marwin Ko; Hope Liou; Max Mahoney; Shadi Ferdosi; Eltaher M Elgierari; Craig Stolarczyk; Behzad Tangeysh; Hongwei Xia; Ryan Benz; Asim Siddiqui; Steven A Carr; Philip Ma; Robert Langer; Vivek Farias; Omid C Farokhzad
Journal:  Nat Commun       Date:  2020-07-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.